The NIAID CIVICs Program was recently featured in a special issue of the journal Vaccine. A variety of CIVICs-funded vaccine studies and promising candidates were highlighted in this issue.
Coronaviruses and influenza viruses pose a major risk to global health, underscored by the impact of the COVID-19 pandemic and continuing spread of SARS-CoV-2 variants.
The National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program is addressing critical gaps in the prevention and control of influenza